In line with these results, in the randomised, placebo-controlled SUSTAIN 5 trial of once-weekly subcutaneous semaglutide as an add-on to basal insulin, the insulin dose was significantly decreased from baseline with both the semaglutide 0.5 and 1.0 mg doses compared with placebo [38]
Not everyone needs or tolerates a GLP-1
It promotes satiety, helping to reduce food intake, which supports weight management and loss
The timeline for results varies greatly depending on the individuals health status and treatment goals
Benhamed M, Martin-Magniette ML, Taconnat L, Bitton F, Servet C, De Clercq R, De Meyer B, Buysschaert C, Rombauts S, Villarroel R, Aubourg S, Beynon J, Bhalerao RP, Coupland G, Gruissem W, Menke FL, Weisshaar B, Renou JP, Zhou DX, Hilson P (2008) Genome-scale Arabidopsis promoter array identifies targets of the histone acetyltransferase GCN5
Buy it here on Amazon Lets meet your body where it is, not where its pressured to be.